GlassScriptPhysician profile
Roy Allan O Elevazo
NPI 1427489483
$9,598.88
in general payments reported to CMS, 2019-2025
20 companies · $1,705 in 2025
The $1,705 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,508 · 2022: $2,259 · 2023: $2,645 · 2024: $1,482 · 2025: $1,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,812 · Education: $19.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,812.04 |
| Education | $19.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,871.09 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,511.90 | 2021-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,444.26 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,099.06 | 2021-2025 | Trintellix |
| Lundbeck LLC | $739.23 | 2021-2025 | Rexulti |
| Alkermes, INC. | $602.35 | 2021-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $511.58 | 2021-2023 | Uzedy |
| Axsome Therapeutics, INC. | $504.73 | 2022-2025 | Auvelity |
| Noven Therapeutics, LLC | $305.58 | 2023-2025 | Xelstrym, Secuado |
| Supernus Pharmaceuticals, INC. | $215.28 | 2024 | Qelbree |
| Vanda Pharmaceuticals INC. | $174.13 | 2025 | Fanapt |
| Almatica Pharma LLC | $158.41 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Eisai INC. | $148.14 | 2021 | |
| Bausch Health US, LLC | $138.11 | 2021-2024 | Aplenzin |
| Sunovion Pharmaceuticals INC. | $44.64 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $37.25 | 2022 | |
| Biogen, INC. | $30.25 | 2022-2023 | |
| Alfasigma USA, INC. | $27.25 | 2022 | |
| Neos Therapeutics, LP | $20.77 | 2025 | Exxua |
| Idorsia Pharmaceuticals US INC | $14.87 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Allan Elevazo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.